VY1706
Alzheimer's Disease
Pre-clinicalActive
Key Facts
About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene therapy company focused on breaking through barriers in neurology. Its core strength lies in the TRACER™ AAV capsid discovery platform, which generates novel vectors with enhanced blood-brain barrier penetration for intravenous delivery. The company is advancing a pipeline targeting major neurological diseases, including Alzheimer's and ALS, and has established strategic partnerships to expand its platform's reach.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Donanemab | Eli Lilly | Phase 3 |
| ALN-APP | Alnylam Pharmaceuticals | Phase 1 |
| Alzheimer's Disease Program | Roche | Various |
| UCB0022 | UCB | Phase 1 |
| Lecanemab (Leqembi) | Eisai | Commercial |
| ARO-MAPT | Arrowhead Pharmaceuticals | Pre-clinical |
| AMBAR® | Grifols | Clinical |
| Lu AG08854 (L1CAM mAb) | Lundbeck | Preclinical |
| DNL919 | Denali Therapeutics | Phase 1b |
| BAN2802 | BioArctic AB | Preclinical |
| Lecanemab SC | BioArctic AB | Phase 3 |
| Undisclosed Program | uniQure | Preclinical |